Joyce M. Slingerland - Publications

Affiliations: 
Biochemistry and Molecular Biology (Medicine) University of Miami, Coral Gables, FL 
Area:
Biochemistry, Oncology

60 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Yoon H, Kim M, Jang K, Shin M, Besser A, Xiao X, Zhao D, Wander SA, Briegel K, Morey L, Minn A, Slingerland JM. p27 transcriptionally coregulates cJun to drive programs of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. PMID 30877256 DOI: 10.1073/pnas.1817415116  0.88
2018 Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29959144 DOI: 10.1158/1078-0432.CCR-17-3697  0.44
2016 Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment. PMID 26993130 DOI: 10.1007/s10549-016-3752-9  0.88
2016 Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, ... ... Slingerland JM, et al. Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. Cancer Research. PMID 26744520 DOI: 10.1158/0008-5472.CAN-15-0927  0.88
2015 Hew K, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford PA, Guo W, Lu Y, Mills GB, Slingerland JM, Simpkins F. MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26482043 DOI: 10.1158/1078-0432.CCR-15-0534  0.88
2015 Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, Creighton CJ, Slingerland JM. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 34: 3107-19. PMID 25151964 DOI: 10.1038/onc.2014.257  0.88
2014 Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Research and Treatment. 144: 503-17. PMID 24567196 DOI: 10.1007/s10549-014-2887-9  0.88
2014 Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nature Reviews. Cancer. 14: 26-38. PMID 24505618 DOI: 10.1038/nrc3622  0.88
2014 Zhou W, Srinivasan S, Nawaz Z, Slingerland JM. ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression. Oncogene. 33: 2341-53. PMID 23770852 DOI: 10.1038/onc.2013.197  0.88
2013 Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. Embo Molecular Medicine. 5: 1502-22. PMID 23982961 DOI: 10.1002/emmm.201302558  0.88
2013 Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment. 138: 369-81. PMID 23430223 DOI: 10.1007/s10549-012-2389-6  0.88
2013 Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annual Review of Medicine. 64: 45-57. PMID 23121183 DOI: 10.1146/annurev-med-121211-091527  0.88
2012 Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, ... ... Slingerland JM, et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5911-23. PMID 22896656 DOI: 10.1158/1078-0432.CCR-12-1257  0.88
2012 Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM. ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. Molecular Endocrinology (Baltimore, Md.). 26: 1567-77. PMID 22865929 DOI: 10.1210/me.2012-1140  0.88
2012 Wen S, So Y, Singh K, Slingerland JM, Resnick MB, Zhang S, Ruiz V, Moss SF. Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer Oncogene. 31: 1771-1780. PMID 21841827 DOI: 10.1038/onc.2011.362  0.88
2012 Sun J, Zhou W, Nawaz Z, Slingerland JM. Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers. 2147483647: 61-78. DOI: 10.1007/978-1-4614-1764-4_4  0.88
2011 Hammes SR, Kelly MJ, Slingerland JM. The physiology of integrated nuclear and extranuclear steroid signaling: introductory comments. Steroids. 76: 821. PMID 21645536 DOI: 10.1016/j.steroids.2011.05.006  0.88
2011 Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. The Journal of Clinical Investigation. 121: 1231-41. PMID 21490404 DOI: 10.1172/JCI44145  0.88
2011 Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 12-8. PMID 20966355 DOI: 10.1158/1078-0432.CCR-10-0752  0.88
2011 Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, Ju Z, Hennessy BT, Slingerland JM. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Research and Treatment. 128: 69-78. PMID 20669046 DOI: 10.1007/s10549-010-1024-7  0.88
2009 Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle (Georgetown, Tex.). 8: 3455-61. PMID 19829074  0.88
2009 Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proceedings of the National Academy of Sciences of the United States of America. 106: 9268-73. PMID 19470470 DOI: 10.1073/pnas.0805057106  0.88
2009 Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3396-405. PMID 19451593 DOI: 10.1158/1078-0432.CCR-08-3127  0.88
2008 Larrea MD, Liang J, Da Silva T, Hong F, Shao SH, Han K, Dumont D, Slingerland JM. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Molecular and Cellular Biology. 28: 6462-72. PMID 18710949 DOI: 10.1128/MCB.02300-07  0.88
2008 Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Molecular Cell. 30: 701-11. PMID 18570873 DOI: 10.1016/j.molcel.2008.04.027  0.88
2008 Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews. Cancer. 8: 253-67. PMID 18354415 DOI: 10.1038/nrc2347  0.88
2007 Sun J, Nawaz Z, Slingerland JM. Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 21: 2651-62. PMID 17666587 DOI: 10.1210/me.2007-0082  0.88
2007 Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. The Journal of Clinical Investigation. 117: 2205-15. PMID 17627304 DOI: 10.1172/JCI21739  0.88
2007 Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nature Cell Biology. 9: 218-24. PMID 17237771 DOI: 10.1038/ncb1537  0.88
2005 Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. Breast Cancer Research : Bcr. 7: R1153-8. PMID 16457695 DOI: 10.1186/bcr1342  0.88
2003 Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle (Georgetown, Tex.). 2: 339-45. PMID 12851486  0.88
2003 Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG, Melchior F, Hengst L, Slingerland JM. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Molecular Biology of the Cell. 14: 201-13. PMID 12529437 DOI: 10.1091/mbc.E02-06-0319  0.88
2002 Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Medicine. 8: 1153-60. PMID 12244302 DOI: 10.1038/nm761  0.88
2002 Donovan JC, Rothenstein JM, Slingerland JM. Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest. The Journal of Biological Chemistry. 277: 41686-92. PMID 12202478 DOI: 10.1074/jbc.M204307200  0.88
2002 Ciarallo S, Subramaniam V, Hung W, Lee JH, Kotchetkov R, Sandhu C, Milic A, Slingerland JM. Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. Molecular and Cellular Biology. 22: 2993-3002. PMID 11940657 DOI: 10.1128/MCB.22.9.2993-3002.2002  0.88
2001 Petrocelli T, Slingerland JM. PTEN deficiency: A role in mammary carcinogenesis Breast Cancer Research. 3: 356-360. PMID 11737885 DOI: 10.1186/bcr322  0.88
2001 Donovan JCH, Milic A, Slingerland JM. Constitutive MEK/MAPK Activation Leads to p27Kip1 Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells Journal of Biological Chemistry. 276: 40888-40895. PMID 11527971 DOI: 10.1074/jbc.M106448200  0.88
2000 Cariou S, Donovan JCH, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27KiP1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells Proceedings of the National Academy of Sciences of the United States of America. 97: 9042-9046. PMID 10908655  0.88
1999 Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma Oncogene. 18: 1023-1032. PMID 10023678 DOI: 10.1038/sj.onc.1202382  0.88
1999 Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27(Kip1) in non-small cell lung carcinoma: A prognostic factor independent of ras Cancer Research. 59: 684-688. PMID 9973218  0.88
1998 Cariou S, Catzavelos C, Slingerland JM. Prognostic implications of expression of the cell cycle inhibitor protein p27(Kip1) Breast Cancer Research and Treatment. 52: 29-41. PMID 10066070 DOI: 10.1023/A:1006154900130  0.88
1998 Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W, Slingerland JM, Amati B. Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene. 17: 2637-43. PMID 9840927 DOI: 10.1038/sj.onc.1202477  0.88
1998 St. Croix B, Sheehan C, Rak JW, Fłorenes VA, Slingerland JM, Kerbel RS. E-cadherin-dependent growth suppression is mediated by the cyclin- dependent kinase inhibitor p27(KIP1) Journal of Cell Biology. 142: 557-571. PMID 9679152 DOI: 10.1083/jcb.142.2.557  0.88
1998 Flørenes VA, Mælandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27(Kip1) in malignant melanoma: Inverse correlation with disease-free survival American Journal of Pathology. 153: 305-312. PMID 9665492  0.88
1998 Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium Cancer Research. 58: 619-621. PMID 9485010  0.88
1998 Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma Cancer Research. 58: 542-548. PMID 9458103  0.88
1997 Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MR. Transforming growth factor β stabilizes p15(INK4B) protein, increases p15(INK4B)-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells Molecular and Cellular Biology. 17: 2458-2467. PMID 9111314  0.88
1997 LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes & Development. 11: 847-62. PMID 9106657  0.88
1997 Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer Nature Medicine. 3: 227-230. PMID 9018244 DOI: 10.1038/nm0297-227  0.88
1997 Tsihlias J, Kapusta L, Slingerland JM, Charles Catzavelos G, Deboer G, Klotz LH. Prognostic role of p-27, a cyclin dependent kinase inhibitor (cdk-i) in localized prostate cancer British Journal of Urology. 80: 232.  0.88
1996 Florenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, Slingerland JM. TGF-β mediated G1 arrest in a human melanoma cell line lacking p15(INK4B): evidence for cooperation between p21(Cip1/WAF1) and p27(Kip1) Oncogene. 13: 2447-2457. PMID 8957087  0.88
1996 St. Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS. Impact of the cyclin-dependent kinase inhibitor p27(Kip1) on resistance of tumor cells to anticancer agents Nature Medicine. 2: 1204-1210. PMID 8898746 DOI: 10.1038/nm1196-1204  0.88
1996 Petrocelli T, Poon R, Drucker DJ, Slingerland JM, Rosen CF. UVB radiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints Oncogene. 12: 1387-1396. PMID 8622854  0.88
1995 Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, Hogg D. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma Oncogene. 11: 404-412. PMID 7624155  0.88
1994 Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases Proceedings of the National Academy of Sciences of the United States of America. 91: 5291-5295. PMID 8202483 DOI: 10.1073/pnas.91.12.5291  0.88
1994 Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells Molecular and Cellular Biology. 14: 3683-3694. PMID 8196612  0.88
1993 Slingerland JM, Jenkins JR, Benchimol S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. The Embo Journal. 12: 1029-37. PMID 8458321  0.88
1991 Slingerland JM, Minden MD, Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia Blood. 77: 1500-1507. PMID 2009369  0.88
1991 Slingerland JM, Benchimol S. Transforming activity of mutant human p53 alleles Journal of Cellular Physiology. 148: 391-395. PMID 1918170  0.88
1989 Slingerland JM, Grossman RF, Chamberlain D, Tremblay CE. Pulmonary manifestations of tuberous sclerosis in first degree relatives Thorax. 44: 212-214. PMID 2705152  0.88
Show low-probability matches.